Maravai LifeSciences Announces March 2023 Investor Conference Schedule
03/08/2023 - 08:00 AM
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of March.
On March 15, 2023, at 2:00 p.m. PST, Kevin Herde, Chief Financial Officer, and Deborah Barbara, Vice President, Strategy and Business Development will participate in a fireside chat at the Barclays Global Healthcare Conference being held in Miami, Florida.
On March 21, 2023, at 9:45 a.m. PST, Carl Hull, Chairman of the Board and Interim CEO will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum being held virtually.
A live webcast of the presentations will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events . An archived version of the webcasts will also be available on the Maravai website following the completion of each event.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit www.maravai.com .
Maravai LifeSciences Holdings Inc
MRVI Rankings
#4968 Ranked by Stock Gains
MRVI Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Commercial Services, Miscellaneous Commercial Services
Country
US
City
San Diego
About MRVI
maravai lifesciences catalyzes the growth of successful, entrepreneurial life science companies by providing expertise, capital, processes and systems so that they can continue to serve scientists who are striving to improve human health. current maravai lifesciences portfolio companies provide enabling tools and services in the life sciences research and bioproduction industries that accelerate breakthrough discoveries in areas such as genomics, proteomics, and biotherapeutic development. maravai lifesciences was formed in march 2014 through a partnership with gtcr, a leading private equity firm. our mission is to build a transformative life sciences reagents company by acquiring outstanding businesses and accelerating their growth. since our founding, we have acquired four companies, each a leader in its market segment. vector laboratories has led the market for labeling and detection products used by researchers in immunohistochemistry, immunofluorescence and related techniques. tri
